Metipranolol (Betanol) is a non-selective beta-blocker that is used in the treatment of patients with raised intraocular pressure and glaucoma.
Metipranolol (Betanol) Uses:
-
Elevated intraocular pressure:
- Treatment elevated intraocular pressure in patient with chronic open-angle glaucoma or ocular hypertension.
Metipranolol Dose in Adults:
Metipranolol (Betanol) Dose in the treatment of Elevated intraocular pressure:
- Ophthalmic: 1 drop in the affected eye(s) two times a day
Use in Children:
Not indicated.
Pregnancy Risk Factor C
- In some studies on animal reproduction, adverse events were observed.
- Similar effects to those experienced with systemic beta blocker administration
- To minimize fetal exposure, avoid pregnancy if you must use it.
Metipranolol use during breastfeeding:
- Use caution during lactation.
- To minimize infant exposure, use the lowest effective dose and punctal occlusion.
Dose in Kidney Disease:
No dose adjustment is needed.
Dose in Liver disease:
No dose adjustment is needed.
Side effects of Metipranolol (Betanol):
-
Cardiovascular:
- Angina
- Atrial Fibrillation
- Bradycardia
- Hypertension
- MI
- Palpitation
-
Central Nervous System:
- Anxiety
- Depression
- Dizziness
- Headache
- Nervousness
- Somnolence
-
Dermatologic:
- Rash
-
Gastrointestinal:
- Nausea
-
Neuromuscular & Skeletal:
- Arthritis
- Myalgia
- Weakness
-
Ocular:
- Abnormal Vision
- Blepharitis
- Blurred Vision
- Conjunctivitis
- Discomfort
- Edema
- Eyelid Dermatitis
- Photophobia
- Tearing
- Uveitis
-
Respiratory:
- Bronchitis
- Cough
- Dyspnea
- Epistaxis
- Rhinitis
-
Miscellaneous:
- Allergic Reaction
Contraindications to Metipranolol (Betanol):
- Hypersensitivity to metipranolol and any component of the formula
- Bronchial asthma, history of bronchial asthma;
- severe COPD
- Sinus bradycardia
- Second- and Third-degree AV Block;
- Cardiac failure
- Cardiogenic shock
Warnings and precautions
-
Anaphylactic reactions
- If you have a history of severe allergic reactions to allergens, such as epinephrine, be cautious.
- Beta-blockers can make patients more sensitive to repeated challenges.
-
Bronchospastic Disease:
- Patients with bronchospastic disorder should not use it.
- If the drug cannot be avoided, use caution.
-
Conductive abnormality
- You should rule out conduction impairments.
-
Diabetes:
- Hypoglycemia may occur and/or symptoms may be masked.
- Take care when administering insulin to diabetic patients.
-
Heart failure:
- Preexisting myocardial dysfunction may be worse (magnitude major).
- Pay attention.
-
Myasthenia gravis:
- Patients with myasthenia gravis should be treated with caution.
-
Peripheral Vascular Disease (PVD).
- Patients with peripheral arterial disease should be cautious.
-
Psychiatric diseases:
- You should be cautious as it may worsen CNS depression.
Metipranolol: Drug Interaction
Note: Drug Interaction Categories:
- Risk Factor C: Monitor When Using Combination
- Risk Factor D: Consider Treatment Modification
- Risk Factor X: Avoid Concomitant Use
Risk Factor C (Monitor therapy) |
|
| Bradycardia-Causing Agents | May enhance the bradycardic effect of other Bradycardia-Causing Agents. |
| Bupivacaine | Beta-Blockers may increase the serum concentration of Bupivacaine. |
| Cholinergic Agonists | Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. |
| EPINEPHrine (Nasal) | Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Nasal). |
| EPINEPHrine (Oral Inhalation) | Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). |
| Epinephrine (Racemic) | Beta-Blockers (Nonselective) may enhance the hypertensive effect of Epinephrine (Racemic). |
| EPINEPHrine (Systemic) | Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Systemic). |
| Ivabradine | Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. |
| Lacosamide | Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. |
| Lidocaine (Systemic) | Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). |
| Lidocaine (Topical) | Beta-Blockers may increase the serum concentration of Lidocaine (Topical). |
| Mepivacaine | Beta-Blockers may increase the serum concentration of Mepivacaine. |
| Methacholine | Beta-Blockers may enhance the adverse/toxic effect of Methacholine. |
| Methoxyflurane | May enhance the hypotensive effect of Beta-Blockers. |
| Midodrine | May enhance the bradycardic effect of Bradycardia-Causing Agents. |
| NIFEdipine | May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers. |
| Opioids (Anilidopiperidine | May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers. |
| Regorafenib | May enhance the bradycardic effect of Beta-Blockers. |
| Reserpine | May enhance the hypotensive effect of Beta-Blockers. |
| Ruxolitinib | May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible. |
| Terlipressin | May enhance the bradycardic effect of Bradycardia-Causing Agents. |
| Theophylline Derivatives | Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. |
| Tofacitinib | May enhance the bradycardic effect of Bradycardia-Causing Agents. |
Risk Factor D (Consider therapy modification) |
|
| Ceritinib | Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib. Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy. Exceptions are discussed in separate monographs. |
| Dronedarone | May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in betablocker dose. |
| Ergot Derivatives | Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. Exceptions: Nicergoline. |
| Fingolimod | Beta-Blockers may enhance the bradycardic effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia. |
| Grass Pollen Allergen Extract (5 Grass Extract) | Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine. Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. |
| Siponimod | Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod. Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. |
Risk Factor X (Avoid combination) |
|
| Beta2-Agonists | Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2Agonists. |
| Fexinidazole [INT] | Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole [INT]. |
| Floctafenine | May enhance the adverse/toxic effect of Beta-Blockers. |
| Rivastigmine | May enhance the bradycardic effect of Beta-Blockers. |
Monitoring Parameters:
Monitor intraocular pressure.
How to administer Metipranolol (Betanol)?
For ophthalmic use only. Avoid dropper contact with skin/ cornea. Remove contact lenses before instilling drops and wait 15 minutes before inserting again.
Mechanism of action of Metipranolol (Betanol):
- Although its mechanism of action is not clear, it is believed to decrease blood flow to the cerebellum, which in turn reduces the production of aqueous humor and thus lowers intraocular pressure.
- Beta blocking agent, but with no intrinsic sympathomimetic or membrane-stabilizing activity and no synaptic activity.
Onset of action:
-
- =30 minutes
Peak effect:
- Maximum: ~2 hours
Duration:
- Intraocular pressure reduction: Up to 24 hours
Metabolism:
- Rapid and complete to deacetyl metipranolol, an active metabolite
Half-life elimination:
- ~3 hours
International Brand Names of Metipranolol:
- Beta Ophtiole
- Betamana
- Betamann
- Betanol
- Disorat
- Glauline
- Minims Metipranolol
- Normoglaucon
- Trimepranol
- Turoptin
Metipranolol Brand Names in Pakistan:
No Brands Available in Pakistan.